Supplementary Table S2. Treatment-Emergent Adverse Events and Vital Signs: Stimulant-Naïve Patients

		Placebo (%) n=*44*	*Edivoxetine 0.1 (%)* n=*40*	*Edivoxetine 0.2 (%)* n=*38*	*Edivoxetine 0.3 (%)* n=*38*	*OROS MPH (%)* n=*36*
Treatment-emergent adverse events (occurring in ≥5% of patients in any edivoxetine group and twice the rate in placebo group)						
Nausea		2.3	10.0	15.8*	23.7*	8.3
Upper abdominal pain		6.8	17.5	5.3	18.4	22.2
Decreased appetite		4.5	7.5	18.4	15.8	47.2*
Vomiting		2.3	12.5	10.5	15.8*	2.8
Aggression		0.0	2.5	0.0	5.3	5.6
Constipation		0.0	2.5	5.3	5.3	2.8
Heart rate increased		0.0	2.5	0.0	5.3	2.8
Irritability		4.5	15.0	18.4	5.3	16.7
Mood altered		2.3	2.5	7.9	5.3	5.6
Initial insomnia		2.3	5.0	2.6	2.6	5.6
Sedation		0.0	5.0	7.9	2.6	8.3
Abdominal pain		0.0	0.0	5.3	0.0	2.8
Dysphoria		0.0	0.0	5.3	0.0	0.0
Eczema		0.0	0.0	5.3	0.0	0.0
Increased appetite		2.3	7.5	0.0	0.0	2.8
Oropharyngeal pain		2.3	2.5	5.3	0.0	5.6
Somnolence		9.1	2.5	18.4	0.0	0.0
Vital signs, weight, and height						
LS mean change from baseline to week 8						
Weight (kg)		0.79	−0.15*	−0.07*	−0.52*	−1.85*
Height (cm)		1.1	1.2	1.1	0.8	0.9
Pulse (bpm) sitting		−2.1	4.8*	10.1*	10.0*	4.5*
Diastolic BP (mmHg) sitting		−0.2	8.1*	5.7*	6.2*	2.9
Systolic BP (mmHg) sitting		2.1	6.6	6.2	5.0	2.8
Percentage of patients with potentially clinically significant QTc changes at any time						
QTc Fridericia's >30 ms increase		0.0	2.8	2.9	0.0	2.9
QTc Fridericia's >450 ms increase		0.00	2.8	2.9	0.0	0.0
Percentage of patients with a categorical shift in BP						
Sitting diastolic BP increase	At end-point	2.3	10.5	8.3	5.6	5.7
≥5 mmHg and ≥95th percentile	At any time	11.4	26.3	30.6*	30.6*	11.4
Sitting systolic BP increase	At end-point	9.1	7.9	8.3	2.8	2.9
≥5 mmHg and ≥95th percentile	At any time	20.5	21.1	30.6	19.4	25.7

*$p < 0.05$ vs. placebo.
0.1 = 0.1 mg/kg/day; 0.2 = 0.2 mg/kg/day; 0.3 = 0.3 mg/kg/day.
BP, blood pressure; LS, least squares; QTc, corrected QT interval.